← Leaderboards
Kevin Luk
Univ Of Massachusetts Med Sch Worcester
$65,162
Attributed
$65,162
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $32.8K · FY2019–20$50K$37.5K$25K$12.5K$0
'19
'20
Funding mix
By agency
NIH$65,162 · 1
By mechanism
F31$65,162 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of Massachusetts Med Sch Worcester
Same institution · by research overlap
- Guang-Ping Gao$18,861,560
- Jonathan K Watts$5,302,344
- Peter E Newburger$12,720,934
- Shaoguang Li$10,655,005
- Jeanne Bentley Lawrence$23,808,064
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectAdultAllogenicAnemiaAutologousAllogeneic Bone Marrow TransplantationBetacell TherapyBeta GlobinBeta ThalassemiaBinding SitesBiological ModelsBone MarrowCd34 GeneCell LineCell LineageCellsChimera OrganismChimeric ProteinsChromosomal RearrangementClinical ResearchClustered Regularly Interspaced Short Palindromic RepeatsComplexCurative TreatmentsDeep Sequencing
Grant awards (2)
Amelioration of Beta-hemoglobinopathies by efficient precise deletion of the +58 BCL11A enhancer using orthogonal Cas9-Cas9 chimeras$32,833
F31 · FY2020 · HL · contact PI
Amelioration of Beta-hemoglobinopathies by efficient precise deletion of the +58 BCL11A enhancer using orthogonal Cas9-Cas9 chimeras$32,329
F31 · FY2019 · HL · contact PI